Zhen Li,Tao Pei,Steven B Kanner,Rui Zhu,Stacey Melquist,Lauren J Almeida
申请号:
US16524822
公开号:
US20190382763A1
申请日:
2019.07.29
申请国别(地区):
US
年份:
2019
代理人:
摘要:
RNA interference agents for inhibiting the expression of Factor XII (FXII) gene are described. Pharmaceutical compositions comprising one or more FXII RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in Vivo are also described. Delivery of the FXII RNAi agent(s) to liver cells in vivo provides for inhibition of FXII gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.